Spotlight On... Sun closing Ranbaxy plant in Ireland; U.K. finds fault with Alkem plant; Serbia seeks investment in Galenika; and more...

sun pharma building

Sun Pharmaceutical will lay off about 70 workers and close a plant in Ireland as it cuts back its manufacturing network following its buyout of Ranbaxy Laboratories last year. Sun had put the plant up for sale last year but was unable to find a buyer. According to the Irish Times, a company statement said the plant would close by the end of the year but the company intends to move some jobs to other facilities in its network. "The Cashel facility closure is being implemented as part of this plan to right size the company's global manufacturing activities," said a statement sent to the newspaper. "We expect to cease operations at Cashel by end of current calendar year." Story | More

> Indian drugmaker Alkem Laboratories says the U.K.'s inspectors noted 8 observations during an inspection of a plant in Taloja, Maharashtra. Report

> Indian drugmaker Makers Pharma says it will sell a plant in Thane. Report

Sponsored by Lubrizol Life Science

[Webinar] Cannabinoid Formulation - from Farm to Pharma

Wednesday, June 24, 2020 | 12pm ET / 9am PT

A handful of cannabinoid-based pharmaceutical products are on the market today, and an ever-growing number are in the global development pipeline. This webinar will explore key considerations in developing cannabinoid-based pharmaceutical products, including an overview of global pharmaceutical cannabinoid usage today, common challenges formulating with CBD and other cannabinoids, and more.

> Serbia is inviting bids for a 25% share in its debt-laden and money-losing pharma company, Galenika. Story

Read more on

Suggested Articles

The FDA asked five drugmakers to pull their version of extended-release metformin off U.S. shelves after finding carcinogen contamination.

The FDA backtracked on its earlier testing and found NDMA contamination in the extended release formulation of certain generic versions of metformin.

GSK has formed several collaborations across the globe that will use its AS03 adjuvant to develop vaccines against the novel coronavirus.